Okyanos Heart Institute treats patients with coronary artery disease with their own stem cells. This presentation is part of a free educational seminar. More information can be found at http://www.okyanos.com
Top Rated Bangalore Call Girls Richmond Circle ⟟ 9332606886 ⟟ Call Me For Ge...
Okyanos Heart Institute Stem Cell Therapy Educational Seminar
1. A FAMILY GUIDE TO
CARDIAC STEM CELL
THERAPY
Restore Flow;
Restore Life
2. Interventional Cardiologist, over 25 years
• University of Georgia, BS
• Medical College of Georgia, M.D.
• Emory University, MBA.
• Vanderbilt University, Fellowship
Former Chief, Cardiac Sciences, Saint
Thomas Hospital, Nashville, Tennessee
American College of Cardiology, Trustee
American Heart Association, Former
President, Davison County Chapter
Howard T. Walpole, M.D.
Chief Medical Officer
Okyanos Heart Institute
More than 17,000 cardiac catheterizations
Howard T. Walpole, MD, MBA, FACC, FACAI
Chief Medical Officer
3. Leslie Miller, MD, FACC
Chief Science Officer, Okyanos
Chair, Department of Cardiovascular Medicine,
University of South Florida (USF)
Director/CEO , USF Cardiovascular Clinical and
Research Integrated Strategic Program
World-renowned cardiologist, specifically in the
areas of heart failure and transplant.
Former Director, Cardiac Programs, Georgetown
University School of Medicine, Georgetown
University Hospital and Washington Hospital Center.
Professor/Director, Cardiovascular Division,
University of Minnesota.
Investigator in over 80 clinical
trials including the use of
adipose-derived stem and
regenerative cells for the
treatment of cardiovascular
disease.
4. Gretchen Dezelick, RN, BSN, CNOR, LHCRM
Director of Nursing
Over 25 years of nursing
experience
Certified Critical Care Nurse
(CCRN) for more than 20 years
Certified Peri-Operative Nurse
(CNOR)
Licensed Healthcare Risk Manager
(LHCRM)
Oversees care delivery & safety
standards
Represents nursing as a member
of the senior leadership team
R.N., St. Joseph Hospital School
of Nursing, Lancaster, PA
BSN, Millersville State
University, PA
• American Association of
Critical Care Nurses
• Association for Professionals in
Infection Control
• Association of Peri-Operative
Registered Nurses
• Florida Society of Healthcare
Risk Managers
• American Society for
Healthcare Risk Management
and Ambulatory Surgery
Center Association.
7. Medical Advisory Council
Eric Duckers, MD, PhD, FESC, FACC
Erasmus University, Netherlands
Leslie Miller, MD, FACC
University of South Florida
Farrell Mendelsohn, MD, FACC
Center for Therapeutic Angiogenesis
Antonio Colombo, MD,
FACC
Columbus Hospital, San
Raffaele Hospital
8. Evolution of Medicine
Cardiac stem cell therapy promises to be a new
phase in the treatment of coronary artery disease.
Past Future
10. 10
EU
FDA
EU Ahead of FDA with Comparable Safety
An English Speaking Country Recognizing
European Union (EU) Standards Convenient
to No-Option Patients
12. PRECISE: Sustained Functional Benefit
Direct Injection Into Heart Muscle via Catheter
19
15.5
15.3
16.6
17.2 17.1
14.0
15.0
16.0
17.0
18.0
19.0
20.0
Baseline 6 Months 18 Months
Control
Cell
MVO2(%)
p < 0.05 p < 0.05
Transplant
13. Okyanos Treatment
• Unique mixture of stem and regenerative cells. Trial
evidence demonstrates that new blood vessels begin, and
damaged heart muscle starts to heal itself.
• Boosts your body's ability to heal itself.
• Delivered via a catheter into the heart for optimal placement
vs. a syringe passing through bloodstream.
• Derived from adipose tissue with 2400 times
more stem cells than from bone marrow.
•Only EU Approved cell-processing device available today.
14. Adipose Derived Regenerative Cells
(ADRCs)
Celution™ is an approved European
Union
cell processing device.
“Fresh cells from adipose-
tissue using the Celution™
system seems to have the
most dramatic results of any
cell therapy study I have
seen in Chronic Ischemic
Heart Disease.”
Francisco Fernandez-Aviles
MD, PhD
15. We Know..
Many Trial Patients
Are Living Better &
Longer than Expected
Cardiac Cell
Therapy is Not (Yet)
a “Cure”
18. When to consider cell therapy?
For continuing symptoms of heart failure despite bypass
surgery and/or stents, such as shortness of breath and
chest discomfort.
In patients with progressively worsening heart function with
or without symptoms.
For patients with evidence of inadequate cardiac blood flow.